FDA Grants Priority Review To Roche Holding AG's Breast Cancer Drug Being Developed With ImmunoGen Inc-Reuters


Tuesday, 6 Nov 2012 05:47pm EST 

Reuters reported that Roche Holding AG said U.S. health regulators granted a priority review to its experimental breast cancer drug TDM-1, expediting the review process for the marketing application of the drug. The U.S. Food and Drug Administration will announce its decision on the marketing approval by February 26. TDM-1, or trastuzumab emtansine, is being developed with ImmunoGen Inc, using ImmunoGen's targeted antibody payload delivery technology. 

Company Quote

37.88
0.51 +1.38%
18 Sep 2014